Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 天前评分70
正文 · 机器翻译
postMONARCH III期试验总生存期结果：abemaciclib + fulvestrant 对比 placebo + fulv，用于在接受既往 CDK4/6 抑制剂联合内分泌治疗后进展的 HR+ HER2- 晚期乳腺癌 https://www.annalsofoncology.org/article/S0923-7534%2826%2908075-0/fulltext #ESMO26 @OncoAlert @KalinskyKevin @Annals_Oncology
126 浏览 · 4 赞 · 4 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Stephanie Graff, MD, FACP, FASCO · x.com